v3.25.2
Other Operating Income and Expenses - Schedule of Other Operating Income and Expenses (Details) - JPY (¥)
¥ in Millions
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Other operating income:      
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 27) ¥ 2,390 ¥ 0 ¥ 0
Gain on sales of property, plant and equipment and investment property 363 144 2,094
Gain on divestment of business to Teva Takeda Yakuhin 10,198 7,832 6,807
Gain on divestment of business and subsidiaries (Note 19) 6,081 7,243 0
Change in estimate of liabilities related to SHP647 0 0 4,102
Other 13,262 11,404 12,421
Total 26,212 19,379 25,424
Other operating expenses:      
Donations and contributions 7,663 7,009 7,685
Restructuring expenses (Note 23) 128,133 81,358 59,234
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 27) 1,788 20,757 3,991
Valuation reserve for pre-launch inventories (reversal) (7,313) 11,052 9,466
Impairment of assets held for sale (Note 19) 6,812 1,685 4,693
Other 69,650 84,666 60,178
Total 206,733 206,527 145,247
Teva Takeda Pharma Ltd.      
Other operating income:      
Gain on divestment of business to Teva Takeda Yakuhin ¥ 4,117 ¥ 588 ¥ 6,807